statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen, is now...

ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe

CDXC's total volume now sits at 628.2K. The +1.32% price change was insignificant, leaving IBM's price at $3.84...

The volume for ChromaDex stock increased for one day, resulting in a record-breaking daily growth of 215% of the 65-Day Volume Moving Average

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen product portfolio is now third-party...

ChromaDex Announces Tru Niagen is Now Third-Party Verified Through the Alkemist Assured Transparency Program

ChromaDex Co. (NASDAQ:CDXC  Get Free Report) was the target of a large decline in short interest in February. As of February 29th, there was short interest totalling 1,210,000 shares, a...

Short Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0%

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ChromaDex price target raised by $1 at H.C. Wainwright, here's why

ChromaDex GAAP EPS of $0.00 beats by $0.02, revenue of $21.2M beats by $0.46M...

ChromaDex GAAP EPS of $0.00 beats by $0.02, revenue of $21.2M beats by $0.46M

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million...

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Analysts at StockNews.com started coverage on shares of ChromaDex (NASDAQ:CDXC  Get Free Report) in a note issued to investors on Sunday. The brokerage set a strong-buy rating on...

ChromaDex (NASDAQ:CDXC) Now Covered by StockNews.com

ChromaDex Corp. (NASDAQ:CDXC) (the Company), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to...

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

ChromaDex (NASDAQ:CDXC  Get Free Report) was upgraded by equities research analysts at StockNews.com from a buy rating to a strong-buy rating in a research note...

ChromaDex (NASDAQ:CDXC) Raised to Strong-Buy at StockNews.com

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Volume	1,549.00
52-Wk High	$4.65
52-Wk Low	$1.25

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.02	--	--	N/A
Q4'23	-$0.02	$0.00	100.00%	BEAT
Q3'23	-$0.03	$0.00	116.28%	BEAT
Q2'23	-$0.04	-$0.03	25.00%	BEAT
Q1'23	-$0.05	-$0.03	35.60%	BEAT

CDXC Chromadex Corp

About

Feed

News

Sentiment

Earnings

Fundamentals